Targeting Platinum Resistant Disease in Ovarian Cancer

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)


Volume 22, 38 Issues, 2015


Download PDF Flyer




Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 6th of 59 in Chemistry & Medicinal
  • 47th of 254 in Pharmacology & Pharmacy
  • 81st of 289 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.853
5 - Year: 4.115

Targeting Platinum Resistant Disease in Ovarian Cancer



Current Medicinal Chemistry, 21(26): 3009-3020.

Author(s): S.L. Morgan, J.E. Medina, M.M. Taylor and DM Dinulescu.

Affiliation: Brigham and Women's Hospital, Harvard Medical School, Eugene Braunwald Research Center, 221 Longwood Ave. 401a, Boston, MA 02215, USA.

Abstract

Ovarian cancer is an extremely aggressive disease in which the vast majority of patients face a very poor prognosis. Although most patients initially respond to current chemotherapeutic regimens that include a combination of platinum- based therapy (cisplatin/carboplatin) and paclitaxel, the vast majority of them quickly relapse and develop increased resistance to available treatments. Thus, intrinsic and acquired chemotherapy resistance is a major obstacle in the treatment of ovarian cancer patients. Consequently, the priorities for basic and translational ovarian cancer research need to include the identification of novel therapies directed against key molecular targets and signaling pathways in platinum resistant disease. At the same time, we need to develop novel systems for drug delivery aimed at increasing the efficacy and reducing the toxicity of platinum-based treatments. Improving the current responses to platinum chemotherapy is critical not only for achieving a better outcome clinically, including a longer survival, but also for allowing patients to have a better quality of life while in treatment.

Keywords:

Combination therapy, CSC pathways, nanotechnology based platforms, oncomap and tumor sequencing, ovarian cancer stem cell markers, platinum resistance.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 21
Issue Number: 26
First Page: 3009
Last Page: 3020
Page Count: 12
DOI: 10.2174/0929867321666140414102701
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2015 Bentham Science